Browsing Tag
biotech acquisition
8 posts
XORTX surges after $3M Vectus Biosystems deal adds promising anti-fibrotic kidney drug to pipeline
Find out how XORTX’s $3 million Vectus Biosystems acquisition could reshape the renal fibrosis market and accelerate its transformation into a leading kidney disease innovator.
Analysts weigh Bristol Myers Squibb’s $1.5bn Orbital Therapeutics deal as a bold but risky pivot
Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics aims to advance in vivo CAR T for autoimmune diseases and strengthen its RNA platform.
Wall Street reacts as Johnson & Johnson circles Protagonist Therapeutics in a potential multibillion-dollar buyout
Explore how Johnson & Johnson’s bid to acquire Protagonist Therapeutics could reshape its immunology and hematology pipeline—details inside.
Is Ocular Therapeutix the next big biotech buyout? Takeover rumors spark investor frenzy
Ocular Therapeutix stock jumps on takeover rumors. Find out what analysts are saying, and why Axpaxl could make it biotech’s next big M&A target.
AbbVie’s $1.2bn bet on Gilgamesh’s bretisilocin signals a bold push into next-generation antidepressants
AbbVie to acquire Gilgamesh’s bretisilocin for up to $1.2B to expand its psychiatry pipeline. Find out how this short-acting psychedelic could reshape MDD care.
AbbVie to acquire Capstan Therapeutics for $2.1bn to expand in vivo CAR-T platform for autoimmune therapy
AbbVie will acquire Capstan Therapeutics for $2.1B, gaining in vivo CAR-T platform and lead asset CPTX2309 in autoimmune therapy. Read full acquisition details.
From biosimilars to biotech gold: How Momenta scored a $6.5bn exit with J&J
Johnson & Johnson is acquiring Momenta Pharmaceuticals for $6.5 billion to expand its autoimmune pipeline. Find out what makes nipocalimab worth the bet.
Biogen to acquire Nightstar Therapeutics in a deal worth $800m to target retinal diseases
In a significant move within the biotech sector, Biogen, the US-based biotechnology giant, has announced its agreement to…